Armando Anido
CIK 1219866 · Chairman & Chief Exec. Officer · last filed 2025-06-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AUXL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
13TH FLOOR
JERSEY CITY, NJ 07302
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SCYX | Director | 8,875 | $3.81 | $33.8K | $31.2K | 11 | 2025-06-30 |
| Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Chairman & Chief Exec. Officer | 0 | $1.30 | $0 | $130.0K | 17 | 2023-10-11 |
| AVIR | Director | — | $4.16 | — | $0 | 2 | 2017-05-22 |
| Vaxart, Inc. (BOTA) Delisted | Director | — | — | — | $0 | 1 | 2015-10-21 |
| PATH | Chief Executive Officer | 1,270,000 | $14.30 | $18.16M | $0 | 4 | 2013-01-22 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | CEO & President | 77,267 | — | — | -$3.71M | 26 | 2011-10-11 |
| RPRX | Director | 2,612 | $64.76 | $169.2K | $0 | 5 | 2010-05-19 |
Recent Filings · Page 2 of 7
70 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-22 | SCYX | Grant (A) | +10,000 | $0 | EDGAR |
| 2022-01-28 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | +120,000 | $0 | EDGAR |
| 2021-06-21 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2021-03-31 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2021-01-25 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | +107,911 | $0 | EDGAR |
| 2020-12-23 | SCYX | Mixed | +5,000 | $31.2K | EDGAR |
| 2020-07-08 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2020-02-03 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-20 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2019-01-30 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.